中国麻风皮肤病杂志 ›› 2026, Vol. 42 ›› Issue (5): 344-347.doi: 10.12144/zgmfskin202605344

• 论著 • 上一篇    下一篇

阿布昔替尼治疗老年中重度特应性皮炎真实世界疗效与安全性分析

梅娅捷1,苏飞1,2,陈慧1,姜敏1   

  1. 1武汉市第一医院皮肤科，湖北武汉，430022；2离岛医疗综合体北京协和医院澳门医学中心皮肤科，中国澳门,999078
  • 出版日期:2026-05-15 发布日期:2026-05-11

Real-world efficacy and safety of abrocitinib in elderly patients with moderate-to-severe atopic dermatitis

MEI Yajie1, SU Fei1,2, CHEN Hui1, JIANG Min1   

  1. 1 Department of Dermatology, Wuhan No.1 Hospital, Wuhan 430022, China; 2 Department of Dermatology, The Islands Healthcare Complex-Macao Medical Center of Peking Union Medical College Hospital, Macao 999078, China
  • Online:2026-05-15 Published:2026-05-11

PDF (PC)

8

摘要： 目的：评估阿布昔替尼在真实世界中治疗老年（≥65岁）中重度特应性皮炎（AD）患者的临床疗效及安全性。方法：本项回顾性研究纳入2023年1月至2024年12月于武汉市第一医院皮肤科就诊，并接受阿布昔替尼（100 mg/d或200 mg/d）治疗的65岁及以上中重度AD患者。主要通过基线至治疗第12周时的湿疹面积及严重程度指数（EASI）和瘙痒峰值数字评价量表（NRS）评分的变化来评估临床疗效。全程监测随访期间的不良事件（AE）。结果：本研究共纳入38例患者。治疗12周时，EASI及NRS评分均较基线显著下降（均P＜0.001）。达到EASI-50、EASI-75及EASI-90的患者比例分别为89.5%、47.4%和2.6%。随访期间，12例（31.6%）患者发生不良事件；2例（5.2%）患者发生严重不良事件（SAE），包括1例结直肠恶性肿瘤及1例心血管事件（冠心病）。结论：阿布昔替尼在真实世界中治疗老年中重度AD患者短期疗效确切。虽然安全性总体可控，但鉴于恶性肿瘤及心血管事件等严重不良事件的发生，尤其是考虑到该人群的基础共病及年龄相关风险，临床应用时必须进行严格的风险获益评估并加强安全监测。

关键词: 特应性皮炎, 阿布昔替尼, 真实世界研究, 老年, JAK抑制剂

Abstract: Objective: To evaluate the clinical efficacy and safety of abrocitinib in the treatment of elderly patients(≥65 years old) with moderate-to-severe atopic dermatitis (AD) in a real-world setting. Methods: This retrospective study included patients aged ≥65 years with moderate-to-severe AD treated with abrocitinib (100 mg/d or 200 mg/d) at the Department of Dermatology, Wuhan First Hospital, between January 2023 and December 2024. Clinical outcomes were assessed based on changes in the Eczema Area and Severity Index (EASI) and the Peak Pruritus Numerical Rating Scale (NRS) from baseline to Week 12. Adverse events (AEs) were monitored throughout the follow-up period. Results: A total of 38 patients were included. At Week 12, both EASI and NRS scores showed significant reduction compared to baseline (Ps＜0.001). The proportions of patients achieving EASI-50, EASI-75, and EASI-90 were 89.5% , 47.4% , and 2.6% , respectively. Adverse events occurred in 12 patients (31.6%), and serious adverse events (SAE) occurred in 2 patients (5.2%), including 1 case of colorectal malignancy and 1 case of cardiovascular event (coronary heart disease). Conclusion: Abrocitinib demonstrates robust short-term efficacy in elderly patients  with moderate-to-severe AD in a real-world context. While the safety profile is generally manageable, the occurrence of SAEs, including malignancy and cardiovascular events, underscores the need for rigorous risk-benefit assessment and enhanced safety monitoring in this specific population, particularly given their underlying comorbidities and age-related risks.

Key words: atopic dermatitis, abrocitinib, real-world study, elderly, JAK inhibitor